Tirzepatide’s CV Benefit; PREVENT Age Calculator; Rectal Injection for BP Reduction?

By News Health
4 weeks Ago

(MedPage Today) — The GIP/GLP-1 dual agonist tirzepatide (Mounjaro) showed cardiovascular protective benefits over dulaglutide (Trulicity) in the phase III SURPASS-CVOT trial of diabetes patients with heart disease, Lilly announced.
The FDA approved…

Source link : https://www.medpagetoday.com/cardiology/generalcardiology/116835

Author :

Publish date : 2025-08-05 17:02:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

High-Dose Flu Shot May Cut Some Hospitalizations in Older Adults

'Slimming jabs have changed the way we do things'

Novel Oral Agent Proves Mettle in Obstructive Hypertrophic Cardiomyopathy

State Laws on Unilateral Decisions for Life Support Are All Over the Map

Getting a COVID Shot Just Became Much More Difficult. Here's Why.

'Weekend Warriors' See Lower Gout Risk, Similar to Gym Rats